Edwards Lifesciences
- Market cap
- 49.44B
- P/E (TTM)i
- 49.87
- P/Bi
- 4.66
- EPSi
- 1.83
- Div yieldi
- 0.00%
- 52W posi
- 56%
Anonymous reader poll. Unscientific, not investment advice.
Edwards Lifesciences last traded at 85.78, down 0.81% on the session. That leaves the company valued at approximately 49.44B, the #442 most valuable US-listed company we track. Trading at a P/E of 50.19, the stock is 51% above its own five-year norm of 33.26. Wall Street's 17-analyst consensus lands on Buy, with a price target averaging 103.40 (+21% from here). Over the past year the stock has ranged from 72.30 to 96.29; it now sits 56% up that band.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 5 months.
- Recent price momentum is +1.1% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 1.6% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation D-
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 50.7x | Better than 12% |
| Forward P/E | 28.1x | Better than 24% |
| Price / Sales | 7.6x | Better than 15% |
| P/E vs own 5-yr range | 92nd pctl | Better than 10% |
Growth B-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 10.8% | Better than 67% |
| Net income CAGR (3Y) | -11.0% | Better than 23% |
| Free cash flow CAGR (3Y) | 11.9% | Better than 52% |
Profitability B+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 78.0% | Better than 90% |
| Operating margin | 27.0% | Better than 81% |
| Net margin | 17.7% | Better than 69% |
| Return on equity | 10.6% | Better than 40% |
| Return on invested capital | 8.7% | Better than 50% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -8.0% | Better than 33% |
| 6-month return | 7.9% | Better than 54% |
| 12-month return (ex latest month) | 17.4% | Better than 53% |
| Distance below 52-week high | 9.4% | Better than 78% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.7x | Better than 88% |
| Debt to assets | 5.2% | Better than 86% |
| Interest coverage | 63.4x | Better than 90% |
| Free cash flow / net income | 124.4% | Better than 60% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 82.4% | Better than 62% |
| Upside to average target | 18.5% | Better than 36% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 86.48
- Open
- 86.65
- Day range
- 85.49 - 87.30
- Avg price
- 86.10
- Volume
- 3.51M
- Turnover
- 302.04M
- Turnover ratei
- 0.61%
- Volume ratioi
- 0.99
- Amplitudei
- 2.09%
- 52-week rangei
- 72.30 - 96.29
Valuation
- P/Ei
- 46.87
- P/E (TTM)i
- 49.87
- P/Bi
- 4.66
- EPSi
- 1.83
- Book value / shi
- 18.42
- Net profit
- 1.05B
- Net assets
- 10.62B
Share structure
- Market cap
- 49.44B
- Float capi
- 49.28B
- Shares out
- 576.40M
- Float sharesi
- 574.49M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
10.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-97.32M net over the window
Short interest
- Shares short
- 9.09M
- % of floati
- 1.58%
- Days to coveri
- 3.15
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Edwards Lifesciences (EW)?
Edwards Lifesciences last traded at 85.78. The quote on this page refreshes every few seconds while US markets are open.
What is Edwards Lifesciences's market cap?
About 49.44B.
What is the P/E ratio of Edwards Lifesciences?
The trailing twelve-month P/E is 49.87, above its own 5-year average of 33.26 — toward the top of its historical range (92.50% percentile). See the Valuation tab for the full history.
Does Edwards Lifesciences pay a dividend?
Edwards Lifesciences does not currently pay a regular dividend.
Is Edwards Lifesciences a buy according to analysts?
The consensus of 17 analysts is a Buy rating, with an average 12-month price target of 103.40, which implies 20.5% upside from the current price. This is not investment advice.
What is Edwards Lifesciences's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Edwards Lifesciences a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-10-08 04:00:07 · For reference only, not investment advice and not tailored to your situation.